CryoLife, Inc. (NYSE:CRY) Director James Benson sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

CryoLife, Inc. (NYSE:CRY) traded up 1.28% during trading on Thursday, hitting $23.80. The stock had a trading volume of 98,128 shares. The firm has a 50 day moving average of $21.31 and a 200-day moving average of $18.95. The stock has a market cap of $796.01 million, a price-to-earnings ratio of 72.12 and a beta of 0.92. CryoLife, Inc. has a 12 month low of $14.03 and a 12 month high of $23.80.

CryoLife (NYSE:CRY) last announced its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. The firm had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.13 earnings per share. Equities analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/05/cryolife-inc-cry-director-james-benson-sells-2000-shares.html.

Several equities analysts recently issued reports on the company. BidaskClub cut CryoLife from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $22.33.

Institutional investors and hedge funds have recently made changes to their positions in the company. Municipal Employees Retirement System of Michigan grew its holdings in shares of CryoLife by 3.2% during the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 190 shares during the last quarter. Mason Street Advisors LLC lifted its position in CryoLife by 7.4% during the first quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 438 shares during the period. State of Alaska Department of Revenue lifted its position in CryoLife by 80.8% during the second quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 2,407 shares during the period. First Mercantile Trust Co. lifted its position in CryoLife by 5.6% during the second quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock valued at $109,000 after purchasing an additional 291 shares during the period. Finally, Creative Planning lifted its position in CryoLife by 3.0% during the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 200 shares during the period. 68.44% of the stock is currently owned by hedge funds and other institutional investors.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.